X4 PHARMACEUTICALS, INC Restructuring Charges
X4 PHARMACEUTICALS, INC (XFOR) reported Restructuring Charges of $235.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2026-08-06
- X4 PHARMACEUTICALS, INC restructuring charges for the quarter ending 2026-06-30 was $198.00K.
- X4 PHARMACEUTICALS, INC restructuring charges for the quarter ending 2026-03-31 was $37.00K.
- X4 PHARMACEUTICALS, INC restructuring charges for the quarter ending 2025-12-31 was -$196.00K.
- X4 PHARMACEUTICALS, INC restructuring charges for the quarter ending 2018-12-31 was $1.56M.
- X4 PHARMACEUTICALS, INC restructuring charges for fiscal 2025 was $7.01M, a 713.82% increase from fiscal 2024.
- X4 PHARMACEUTICALS, INC restructuring charges for fiscal 2024 was $861.00K.
- X4 PHARMACEUTICALS, INC restructuring charges for fiscal 2018 was $2.00M.
| Period end | Restructuring Charges 3 month | Restructuring Charges 6 month | Restructuring Charges 9 month | Restructuring Charges 12 month |
|---|---|---|---|---|
| 2026-06-30 | $198.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $235.00K 10-Q · filed 2026-08-06 | $39.00K derived: sum of 3 quarters · filed 2026-08-06 | |
| 2026-03-31 | $37.00K 10-Q · filed 2026-05-06 | -$159.00K derived: sum of 2 quarters · filed 2026-05-06 | ||
| 2025-12-31 | -$196.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $7.01M 10-K · filed 2026-03-17 | ||
| 2025-09-30 | $7.20M 10-Q · filed 2025-11-05 | |||
| 2024-12-31 | $861.00K 10-K · filed 2026-03-17 | |||
| 2018-12-31 | $1.56M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-11 | $1.97M derived: sum of 2 quarters · filed 2019-03-11 | $2.00M 10-K · filed 2019-03-11 | |
| 2018-09-30 | $400.00K 10-Q · filed 2018-11-09 | $430.00K 10-Q · filed 2018-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |